Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mu Sun

Showing results (281-290 of 338) with videos related to

Pageof 34
Sort By:
Genomics|February 26, 2013
Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatmentDonghui Huang, Dong-Wan Kim, Athanasios Kotsakis, et al.
Anticancer Research|November 14, 2013
High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patientsChi Hoon Maeng, Ho Yun Lee, Young Wook Kim, et al.
Cancer Research and Treatment|July 13, 2010
Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapyJina Yun, Kyoung-Mee Kim, Seung Tae Kim, et al.
Human Genetics|August 26, 2011
The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populationsMyung-Ju Ahn, Hong-Hee Won, Jeeyun Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 11, 2025
Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter TrialSehhoon Park, Hee Kyung Ahn, Seoyoung Lee, et al.
Cancer Research and Treatment|June 20, 2018
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent ChemoradiotherapySong Ee Park, Jae Myoung Noh, You Jin Kim, et al.
The Lancet. Oncology|December 25, 2025
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trialJong-Mu Sun, Yee Chao, Sung-Bae Kim, et al.
British Journal of Pharmacology|January 8, 2022
5-HT<sub>3</sub><sub>A</sub> receptors maintain hippocampal LTP in a CB<sub>1</sub> and GABA<sub>A</sub> receptor- dependent manner for spatial memoryYan Yu, Jing-Jing Li, Xiao-Qian He, et al.
Clinical Lung Cancer|July 4, 2017
Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor SamplesJong Ho Cho, Steffen Filskov Sorensen, Yoon-La Choi, et al.
International Journal of Radiation Oncology, Biology, Physics|February 12, 2022
Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 TherapyKyung Hwan Kim, Hongryull Pyo, Hoyoung Lee, et al.
Pageof 34

Showing results (281-290 of 338) with videos related to

Sort By:
Pageof 34
Genomics|February 26, 2013
Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatmentDonghui Huang, Dong-Wan Kim, Athanasios Kotsakis, et al.
Anticancer Research|November 14, 2013
High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patientsChi Hoon Maeng, Ho Yun Lee, Young Wook Kim, et al.
Cancer Research and Treatment|July 13, 2010
Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapyJina Yun, Kyoung-Mee Kim, Seung Tae Kim, et al.
Human Genetics|August 26, 2011
The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populationsMyung-Ju Ahn, Hong-Hee Won, Jeeyun Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 11, 2025
Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter TrialSehhoon Park, Hee Kyung Ahn, Seoyoung Lee, et al.
Cancer Research and Treatment|June 20, 2018
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent ChemoradiotherapySong Ee Park, Jae Myoung Noh, You Jin Kim, et al.
The Lancet. Oncology|December 25, 2025
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trialJong-Mu Sun, Yee Chao, Sung-Bae Kim, et al.
British Journal of Pharmacology|January 8, 2022
5-HT<sub>3</sub><sub>A</sub> receptors maintain hippocampal LTP in a CB<sub>1</sub> and GABA<sub>A</sub> receptor- dependent manner for spatial memoryYan Yu, Jing-Jing Li, Xiao-Qian He, et al.
Clinical Lung Cancer|July 4, 2017
Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor SamplesJong Ho Cho, Steffen Filskov Sorensen, Yoon-La Choi, et al.
International Journal of Radiation Oncology, Biology, Physics|February 12, 2022
Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 TherapyKyung Hwan Kim, Hongryull Pyo, Hoyoung Lee, et al.
Pageof 34